Form 8-K - Current report:
SEC Accession No. 0000950170-23-029731
Filing Date
2023-06-26
Accepted
2023-06-26 08:01:33
Documents
12
Period of Report
2023-06-21
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K stro-20230621.htm   iXBRL 8-K 53793
  Complete submission text file 0000950170-23-029731.txt   172512

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT stro-20230621.xsd EX-101.SCH 2464
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT stro-20230621_lab.xml EX-101.LAB 13654
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT stro-20230621_pre.xml EX-101.PRE 11050
6 EXTRACTED XBRL INSTANCE DOCUMENT stro-20230621_htm.xml XML 4752
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 231039459
SIC: 2836 Biological Products, (No Diagnostic Substances)